Suki AI vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Redwood City ambient voice AI for physicians converting patient conversations into EHR-coded SOAP notes and diagnoses; integrates with major EHR systems to reduce documentation time.
About
Suki AI is a Redwood City-based clinical AI company that provides physicians with an ambient voice assistant that listens to patient-physician conversations during appointments and automatically generates structured clinical notes in the EHR, dramatically reducing the documentation burden that contributes to physician burnout. Suki's AI processes natural conversation audio to extract clinically relevant information, populate SOAP notes, and code diagnoses and procedures — turning a 15-minute documentation task into a 2-minute review and sign-off. The platform integrates with major EHR systems including Epic, Cerner, and Athena and is designed to fit naturally into clinical workflows without requiring physicians to change how they see patients. Suki serves health systems, physician groups, and telehealth companies looking to improve clinician efficiency and satisfaction. Founded in 2017 by former Google and Flipkart executives, Suki raised over $165M from investors including Venrock, First Round Capital, and Flare Capital Partners. It competes with Nuance DAX, Abridge, and DeepScribe in the ambient AI documentation market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.